All News

Global Launch in the IMS Health Era

The sudden departure of EC Health Commissioner John Dalli tops an already difficult year for the European pharma regulators, writes Reflector.

No doubt the November 6th election is going to be close, very close: close for the Presidency, close for the Senate, and possibly close for the House.

Just days before the reports that R&D investment in Spanish pharma had fallen to below EUR1 billion ($1.3 billion) in 2011 for the first time since 2007.

Grey Healthcare Group - Leveraging Your Brand’s Name to Achieve Post-Patent Success

Ethics is a matter of trust, which in the regulatory space requires transparency and openness among all stakeholders, including patients and industry.

Featured panelists at ExL’s annual Digital Pharma East conference this week included practicing physicians, vocal ePatients, social media gurus and digital marketing consultants with plenty of hours logged in big pharma boardrooms.

New stories earlier this year (1) reported that FDA scientists have been suspected of leaking confidential, commercial, and trade secret information to the media.

Lundbeck's Big Bet

S

Developing a drug is still very much a game of chance: a round puzzle of soft edges, with pieces that rarely fit the hard rectangles of time and money. Solving the puzzle correctly-with a new product as the sum of its parts-depends on making that lengthy progression from basic science to registration as linear as possible.

PE Ad Dimensions

PE June 2012 BPA

The furore that burst across Brussels in late September over reported findings of tumors in rats fed with genetically modified maize may seem only tangentially related to the concerns.

The sessions focused heavily on the state of doing business in Brazil.

A recent decision by the Department of Health (DoH) to introduce a compliance regime for NICE (National Institute for Health and Clinical Excellence) technology.

Pharm Exec’s 2012 Industry Audit relies on 2011 data to compare performance against 2010.

Innovation Excellence is a unique application of lean kaizen methodologies and personal coaching. It frees up capacity for innovative research, fosters ownership and significantly enhances the output of your research and innovation teams.

The Access to Medicines Index is an attempt to measure and compare the corporate social responsibility of both innovator (20) and generics (7) companies based on a number of different (and often quixotic) indicators.

The pharmaceutical industry still lags other industries in spending on outbound social media programs that engage customers directly.

The FDA and the Advanced Medical Technology Association (AdvaMed) gave cardiovascular device manufacturers plenty to think about over the holiday weekend with information presented at an Aug. 28 workshop.

Busting the Tape

Autumn is a good time to present our annual post on how well the industry is doing in harvesting value for shareholders. Our diverse list of 24 companies, drawn from Big Pharma to the established biotechs, presents a similarly mixed picture on returns: smaller firms with a distinct customer base and tight oversight of costs are by and large proving more adept at delivering the strong growth that investors still expect from this business.

"Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets."

It’s something of an enigma that most physicians are keen to learn about and use cutting edge medicines and devices for their patients.

In the American version of the Australian TV series Wilfred, the show’s title character declares that for him, human life begins at 10 years old.

Public policy activities should be a distinct, mission critical function for Big Pharma - our business depends increasingly on government as a key customer.